Skip to content

LapBox® Manual Containment System

Evaluation of Leak Integrity of the LapBox® Manual Containment System During Laparoscopic Surgery

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07767968
Enrollment
24
Registered
2026-08-17
Start date
2026-09-01
Completion date
2027-07-01
Last updated
2026-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery

Keywords

laparoscopic hysterectomy, laparoscopic myomectomy, uterine fibroids, morcellation

Brief summary

This study to evaluate the leak integrity of the LapBox Manual Containment System for laparoscopic hysterectomy and myomectomy. The goal is to determine the integrity of this containment system in order to increase surgical safety. 30 adult females who require laparoscopic hysterectomy or myomectomy for management of uterine fibroids will be enrolled and will be on study the day of surgery.

Detailed description

The goal is to determine the integrity of the LapBox Manual Containment system in order to increase surgical safety of morcellation of uterine fibroids during laparoscopic hysterectomy and myomectomy. Containment systems are imperative for laparoscopic morcellation due to the potential for tissue dissemination, particularly in cases of undiagnosed malignancy or benign tissue fragments during morcellation of uterine fibroids. Integrity of the LapBox Manual Containment System will be evaluated by indicating the presence or absence of leakage from testing with methylene blue dye after morcellation. The LapBox and standard of care devices will be moved away from the surgical field prior to methylene blue being added to determine if there is breakage. The methylene blue dye will not come in contact with the participant or spill onto the surgical field. The hypothesis is that laparoscopic hysterectomies and myomectomies performed using the LapBox Manual Containment System will result in less leakage when compared to the control containment system. The primary endpoint will be presence or absence of leakage from the LapBox and the control. This will be directly visualized intraoperatively after morcellation takes place. The secondary endpoint will be the incidence of perforation or rupture incidence in the LapBox or standard of care device and descriptive comments from surgeons for usability feedback.

Interventions

DEVICELapBox Manual Containment System

The LapBox Manual introduces a double wall, pressure resistant system to maintain safe separation between the cutting instrument and chamber wall. The LapBox Manual is already FDA-approved for use so this will be a post-market analysis.

DEVICEStandard of Care Specimen Bag

Meriter has an endoscopic specimen retrieval bag which will be the standard of care specimen bag depending on the size of the uterine fibroids. The bag can be deployed through a 15 mm port. The standard bag is selected depending on the size of the uterine fibroids.

Sponsors

University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Intervention model description

6 participants will be enrolled first for practice with the LapBox device, per protocol, no data will be collected from these participants. This is followed by a randomized investigative trial on 24 patients. Block randomization will occur at the time of surgery after morcellation of uterine fibroids. Patients will be randomized in to 2 groups using different containment systems (1:1 comparing LapBox System vs. standard specimen bag).

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Participants who require laparoscopic hysterectomy or myomectomy for management of uterine fibroids

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Presence or Absence of Leakagedata collected intraoperatively (on day of surgery, only study visit)Integrity will be evaluated by indicating the presence or absence of leakage after morcellation and subsequent testing with methylene blue dye during laparoscopic hysterectomy or myomectomy.

Secondary

MeasureTime frame
Incidence of Perforation or Rupturedata collected intraoperatively (on day of surgery, only study visit)

Countries

United States

Contacts

CONTACTSharon Blohowiak
sblohowiak@wisc.edu(608) 262-5977
PRINCIPAL_INVESTIGATORBala Bhagavath, MD

UW School of Medicine and Public Health

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 18, 2026